OptiBiotix Health PLC Launch of novel prebiotic in Europe and Africa (5247A)
26 Settembre 2022 - 8:00AM
UK Regulatory
TIDMOPTI
RNS Number : 5247A
OptiBiotix Health PLC
26 September 2022
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Launch of novel prebiotic in Europe and Africa
New product will be branded OptiXOS
OptiBiotix Health plc (AIM: OPTI), a life sciences busi ness d
eveloping compounds to tackle obesity, cardiovascular disease and
diabetes, announces it has signed an exclusive distribution
agreement with Shandong Longlive Biotechnology Co Ltd ("Longlive")
for the distribution of Longlive's unique xylooligosaccharide ("
XOS") prebiotic into the human nutrition markets (foods &
beverages and supplements) in Europe and Africa. The product will
be branded OptiXOS.
Longlive is one of the global technology and market leader in
the novel prebiotic XOS. The company has a core capability in corn
and corncob processing into various food ingredients such as
starch, polyols, sugar replacers, monosaccharides and prebiotic
fibres.
XOS is a prebiotic fibre with unique characteristics and
benefits compared to other prebiotic fibres commercially available
in Europe. One gram of XOS is sufficient to have a marked effect on
the growth of healthy favourable gut microbes such as
bifidobacteria and lactobacilli. Its superior stability at high
temperatures and low pH combined with the small effective dose give
it wide applicability within food & beverage applications and
extends its reach to supplement applications requiring pills,
tablets and capsules. XOS is stable in the harsh environment of the
gastrointestinal tract which maximises its effectiveness when it
reaches the gut.
XOS also has a complementary effect on the growth and
propagation of probiotics such as Lactobacillus plantarum and
Lactobacillus rhmanosus (such as LGG). This creates the potential
for probiotic companies to boost the health benefits of their
existing products and create real differentiation in the market.
This application has been researched by OptiBiotix as part of a
joint development with DSM (announced 5 April 2016) and is covered
by an extensive patent portfolio.
Longlive has been successful in obtaining key regulatory
approvals for XOS in the North American market (FDA GRAS and New
Dietary Ingredient, Health Canada) and in 2018 obtained EFSA Novel
Food approval opening up the European market.
OptiXOS comes with an active a pipeline of customer projects
passed on by Longlive and is commercially available to customers
with immediate effect. The new logo for the product is displayed
below.
René Kamminga, C EO of O pti B i oti x Limited, c o mmented :
"XOS is an important addition to OptiBiotix's technology portfolio.
It is a building block that will increase our importance in
microbiome modulation and act as leverage for our more advanced
science based prebiotic solutions in the food & beverage and
supplement industry in Europe & Africa. The agreement with
Longlive is another step for Optibiotix on its path to in-license
or acquire unique technologies to broaden its product portfolio and
reinforce our role as leaders in the microbiome field. We look
forward to working with the team at Longlive to make this link-up
into a significant contributor to our mutual business growth
ambitions."
This announcement contains information which, prior to its
disclosure, was considered inside information for the purposes of
the UK Market Abuse Regulation and the Directors of the Company are
responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSEWFMDEESEIU
(END) Dow Jones Newswires
September 26, 2022 02:00 ET (06:00 GMT)
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Apr 2023 a Apr 2024
